According to study results reported in “Radiology”, researchers have discovered that the coronavirus is linked to fatal blood clots in leg arteries. The researchers stated that coronavirus patients who were in short supply of blood to their lower limbs tended to have bigger clots, and remarkably higher amputation rates and death, especially in comparison with COVID-negative individuals who had identical conditions.
When the pandemic was at its peak in New York, radiologists from a medical center in the Bronx noted a rise in the number of patients who tested positive for lower extremity arterial thrombosis on CT angiography exams. The patients exhibited symptoms of discoloration, pain and coldness on their legs.
This trend led the researchers to investigate a possible link between lower extremity arterial thrombosis and the coronavirus, with the objective of finding out whether individuals who had been infected with COVID-19 had a worse diagnosis.
To do this, during March and April 2020 researchers identified 16 coronavirus patients, with an average age of 70. These patients had CT angiographies of their lower limbs conducted, with researchers observing for any leg ischemia symptoms. They were then compared to another group made up of 32 individuals who were COVID-negative, whose average age was 71. The latter group had had CT angiographies conducted in prior years and were compatible with the coronavirus positive group for clinical and demographic characteristics.
When compared to 69% of the patients in the control group, the researchers found that all the patients who were COVID-positive and underwent lower extremity CT angiography had no less than a single clot in the leg. In addition to this, the clots in the coronavirus-positive patients affected arteries higher up in the leg and were noticeably larger. The researchers noted that limb amputation and death was also prevalent in the coronavirus patients as well.
Inessa A. Goldman, the lead author of the study, explained that the team discovered the arterial thrombosis that was linked to the coronavirus infection was set apart by extremely high rates of death and amputation, which they found to be 38% and 25% respectively. In comparison, the researchers had found the rates of both death and amputation in the control group to be 3%.
Goldman observed that as the coronavirus infection rates rose in the United States, it was critical that physicians be conscious of the link between lower extremity arterial thrombosis and the coronavirus. She added that an early diagnosis of the condition was key in helping preserve a patient’s limbs.
Away from the coronavirus, RYAH Group Inc. is hard at work bringing to market products that utilize data analytics as well as remote health solutions. For example, RYAH has a Smart Patch that can be used to deliver site-specific therapies, such as pain medication.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.